<?xml version="1.0" encoding="UTF-8"?>
<p id="Par52">
 <italic>Remdesivir</italic> (GS-5734; Gilead Sciences Inc., Foster City, CA, USA) is an investigational intravenous drug with broad antiviral activity that inhibits viral replication through premature termination of RNA transcription and has in vitro activity against SARS-CoV-2 as well as in vivo activity against related betacoronaviruses. Unlike other nucleotide analogues, remdesivir is a phosphoramidate prodrug with broad-spectrum activity against many virus families, including 
 <italic>Filoviridae</italic>, 
 <italic>Paramyxoviridae</italic>, 
 <italic>Pneumoviridae</italic>, and 
 <italic>Orthocoronavirinae</italic> (such as pathogenic SARS-CoV and MERS-CoV) [
 <xref ref-type="bibr" rid="CR44">44</xref>].
</p>
